Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease